VPC
Vestal Point Capital Portfolio holdings
AUM
$1.9B
This Quarter Return
+12.07%
1 Year Return
-12.28%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$1.21B
AUM Growth
+$1.21B
(+28%)
Cap. Flow
+$234M
Cap. Flow
% of AUM
19.34%
Top 10 Holdings %
Top 10 Hldgs %
61.52%
Holding
77
New
29
Increased
16
Reduced
11
Closed
19
Top Buys
| 1 |
Cytokinetics
CYTK
|
$147M |
| 2 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$50.8M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
$47.1M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
$45.2M |
| 5 |
NARI
Inari Medical, Inc. Common Stock
NARI
|
$38.4M |
Top Sells
| 1 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$58.1M |
| 2 |
Merck
MRK
|
$43.6M |
| 3 |
CBAY
Cymabay Therapeutics
CBAY
|
$38.4M |
| 4 |
Vaxcyte
PCVX
|
$33M |
| 5 |
Pacira BioSciences
PCRX
|
$32.7M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Praxis Precision Medicines
PRAX
$958M
| $12.8M | 1.06% |
+210,000
| New | +$12.8M |
|
27
Immatics
IMTX
$649M
| $12.6M | 1.04% |
1,200,000
-900,000
| -43% | -$9.46M |
|
28
Incyte
INCY
$16.8B
| $11.4M | 0.94% |
+200,000
| New | +$11.4M |
|
29
MacroGenics
MGNX
$110M
| $10.7M | 0.88% |
+725,000
| New | +$10.7M |
|
30
Agios Pharmaceuticals
AGIO
$2.28B
| $9.5M | 0.79% |
+325,000
| New | +$9.5M |
|
|
SWAV
31
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| $8.14M | 0.67% |
+25,000
| New | +$8.14M |
|
32
Krystal Biotech
KRYS
$4.27B
| $8.01M | 0.66% |
+45,000
| New | +$8.01M |
|
33
KalVista Pharmaceuticals
KALV
$678M
| $7.77M | 0.64% |
+655,000
| New | +$7.77M |
|
34
Geron
GERN
$938M
| $7.26M | 0.6% |
+2,200,000
| New | +$7.26M |
|
35
Arcellx
ACLX
$3.87B
| $6.96M | 0.58% |
100,000
+40,000
| +67% | +$2.78M |
|
36
Exact Sciences
EXAS
$9.09B
| $6.91M | 0.57% |
+100,000
| New | +$6.91M |
|
37
Fulcrum Therapeutics
FULC
$351M
| $6.56M | 0.54% |
695,000
-330,000
| -32% | -$3.12M |
|
38
Viking Therapeutics
VKTX
$3.09B
| $6.15M | 0.51% |
+75,000
| New | +$6.15M |
|
39
Passage Bio
PASG
$22.7M
| $6.08M | 0.5% |
+4,500,000
| New | +$6.08M |
|
40
Allogene Therapeutics
ALLO
$249M
| $6.03M | 0.5% |
+1,350,000
| New | +$6.03M |
|
41
Fate Therapeutics
FATE
$119M
| $5.87M | 0.49% |
800,000
-490,000
| -38% | -$3.6M |
|
42
Voyager Therapeutics
VYGR
$186M
| $5.59M | 0.46% |
+600,000
| New | +$5.59M |
|
43
Relmada Therapeutics
RLMD
$47.1M
| $5.58M | 0.46% |
1,200,000
+1,085,000
| +943% | +$5.05M |
|
44
Bio-Rad Laboratories Class A
BIO
$8.06B
| $5.19M | 0.43% |
+15,000
| New | +$5.19M |
|
45
Ultragenyx Pharmaceutical
RARE
$3.09B
| $5.14M | 0.42% |
+110,000
| New | +$5.14M |
|
46
Lyra Therapeutics
LYRA
$12.2M
| $4.98M | 0.41% |
800,000
-2,200,000
| -73% | -$13.7M |
|
47
Galapagos
GLPG
$2.05B
| $4.19M | 0.35% |
130,000
| – | – |
|
48
Alto Neuroscience
ANRO
$105M
| $3.84M | 0.32% |
+250,000
| New | +$3.84M |
|
49
Lexeo Therapeutics
LXEO
$259M
| $2.74M | 0.23% |
+175,000
| New | +$2.74M |
|
50
Prime Medicine
PRME
$556M
| $2.52M | 0.21% |
360,000
+339,694
| +1,673% | +$2.38M |
|